News
ALVO
3.650
+0.83%
0.030
Alvotech Earnings Call: Growth Momentum Meets FDA Risk
TipRanks · 2d ago
Why nCino Shares Are Trading Higher By 18%; Here Are 20 Stocks Moving Premarket
Benzinga · 2d ago
Alvotech announces availability of fiscal 2025 Form 20-F annual report
Reuters · 4d ago
Alvotech announces publication of FY 2025 annual report
Reuters · 4d ago
Alvotech publishes 2025 annual report
Reuters · 4d ago
Alvotech Files Annual Report with the SEC
Barchart · 4d ago
Alvotech Publishes 2025 Annual Report
Barchart · 4d ago
Weekly Report: what happened at ALVO last week (0323-0327)?
Weekly Report · 4d ago
Alvotech Price Target Cut to $6.00/Share From $10.00 by UBS
Dow Jones · 03/24 14:46
Alvotech Is Maintained at Buy by UBS
Dow Jones · 03/24 14:46
UBS Maintains Buy on Alvotech, Lowers Price Target to $6
Benzinga · 03/24 14:36
Alvotech Is Maintained at Underweight by Barclays
Dow Jones · 03/24 14:13
Alvotech Price Target Cut to $4.00/Share From $5.00 by Barclays
Dow Jones · 03/24 14:13
Barclays Maintains Underweight on Alvotech, Lowers Price Target to $4
Benzinga · 03/24 14:03
Alvotech price target lowered to $4 from $8 at Deutsche Bank
TipRanks · 03/24 12:50
Alvotech price target lowered to $4 from $5 at Barclays
TipRanks · 03/24 09:37
Alvotech: Regulatory Setbacks Priced In, Biosimilar Strength Supports Buy Rating Despite Lowered Target
TipRanks · 03/23 23:35
Alvotech price target lowered to $6 from $10 at UBS
TipRanks · 03/23 23:30
Weekly Report: what happened at ALVO last week (0316-0320)?
Weekly Report · 03/23 09:51
More
Webull provides a variety of real-time ALVO stock news. You can receive the latest news about Alvotech through multiple platforms. This information may help you make smarter investment decisions.
About ALVO
Alvotech SA is a biotechnology company. The Company is focused on the development and manufacture of biosimilar medicines for patients globally. It is engaged in developing a pipeline of monoclonal antibodies that target a variety of therapeutic areas including inflammatory diseases, oncology, and ophthalmology. The Company’s pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. Its products pipeline includes AVT02, AVT04, AVT23, AVT03, AVT05, AVT06, AVT16, and AVT33. Its AVT02 is a monoclonal antibody and a biosimilar to Humira (adalimumab). AVT04 is a monoclonal antibody and a biosimilar candidate to Stelara (ustekinumab). It has formed a network of strategic commercial partnerships to provide global reach and leverage expertise in markets that include the United States (U.S.), Europe, Japan, China, and other Asian countries and large parts of South America, Africa, and the Middle East.